Medannex Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 5

Medannex General Information

Description

Operator of a biopharmaceutical company intended to improve the lives of people impacted by cancers and autoimmune diseases. The company specializes in developing antibodies that specifically target and inhibit annexin-A1 as well as help to modulate the innate and adaptive immune systems to treat diseases, enabling physicians to treat their patients in an enhanced way.

Contact Information

Website
www.medannex.org
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 1 Lochrin Square
  • 92-98 Fountainbridge
  • Edinburgh EH3 9QA
  • Scotland, United Kingdom
+44 0131 000 0000

Medannex Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medannex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 27-Oct-2020 000.00 Completed Clinical Trials - Phase 1
7. Grant 15-Jun-2020 00000 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B) 28-Aug-2019 000.00 000.00 0000 Completed Clinical Trials - Phase 1
5. Later Stage VC 00.000 Completed Clinical Trials - Phase 1
4. Grant 21-Feb-2019 00000 00.000 Completed Clinical Trials - Phase 1
3. Grant 12-Jun-2018 00000 00.000 Completed Startup
2. Later Stage VC 31-Mar-2017 $1.57M $2.84M 000.00 Completed Startup
1. Seed Round 27-Aug-2013 $1.27M $1.27M Completed Startup
To view Medannex’s complete valuation and funding history, request access »

Medannex Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Preference 83,190 $0.000012 $1.46 $1.46 1x $1.46 0.28%
To view Medannex’s complete cap table history, request access »

Medannex Patents

  • 21

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Medannex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202208893-D0 Combination therapy for cancer Pending 16-Jun-2022
GB-202116680-D0 Combination therapy for cancer Inactive 18-Nov-2021
US-20210238269-A1 Cancer treatment with an antibody Pending 10-Aug-2018 0000000000 0
AU-2019319092-A1 Cancer treatment with an antibody Pending 10-Aug-2018 000000000
CA-3107674-A1 Cancer treatment with an antibody Pending 10-Aug-2018 A61K39/395
To view Medannex’s complete patent history, request access »

Medannex Executive Team (4)

Name Title Board Seat Contact Info
Ian Abercrombie Chief Executive Officer & Board Member
Paul Flook Financial Controller
Christopher Wood MD Executive Chairman
You’re viewing 3 of 4 executive team members. Get the full list »

Medannex Board Members (7)

Name Representing Role Since
Christopher Wood MD Self Executive Chairman 000 0000
Hugh Griffith Alida Capital International Board Member 000 0000
Ian Abercrombie Medannex Chief Executive Officer & Board Member 000 0000
Isaac Cheng MD Morningside Group Board Member 000 0000
Keith Lipman Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Medannex Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medannex Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Golden Triangle Partners Venture Capital Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Scottish Enterprise Venture Capital Minority 000 0000 000000 0
Elixir Ventures Venture Capital Minority 000 0000 000000 0
To view Medannex’s complete investors history, request access »

Ready to get started?

Request a free trial